Beam Therapeutics Stock Market Value
| BEAM Stock | USD 26.93 0.94 3.62% |
| Symbol | Beam |
Will Biotechnology sector continue expanding? Could Beam diversify its offerings? Factors like these will boost the valuation of Beam Therapeutics. Projected growth potential of Beam fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Beam Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.25) | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets | Return On Equity |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Beam Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Beam Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Beam Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Beam Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Beam Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Beam Therapeutics.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Beam Therapeutics on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Beam Therapeutics or generate 0.0% return on investment in Beam Therapeutics over 90 days. Beam Therapeutics is related to or competes with Agios Pharm, Denali Therapeutics, Recursion Pharmaceuticals, Immunitybio, Arcus Biosciences, Cogent Biosciences, and Mineralys Therapeutics. Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from seriou... More
Beam Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Beam Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Beam Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.69 | |||
| Information Ratio | 0.0657 | |||
| Maximum Drawdown | 31.78 | |||
| Value At Risk | (6.30) | |||
| Potential Upside | 8.12 |
Beam Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Beam Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Beam Therapeutics' standard deviation. In reality, there are many statistical measures that can use Beam Therapeutics historical prices to predict the future Beam Therapeutics' volatility.| Risk Adjusted Performance | 0.0747 | |||
| Jensen Alpha | 0.2747 | |||
| Total Risk Alpha | (0.04) | |||
| Sortino Ratio | 0.0897 | |||
| Treynor Ratio | 0.2237 |
Beam Therapeutics February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0747 | |||
| Market Risk Adjusted Performance | 0.2337 | |||
| Mean Deviation | 3.43 | |||
| Semi Deviation | 3.44 | |||
| Downside Deviation | 3.69 | |||
| Coefficient Of Variation | 1224.02 | |||
| Standard Deviation | 5.04 | |||
| Variance | 25.41 | |||
| Information Ratio | 0.0657 | |||
| Jensen Alpha | 0.2747 | |||
| Total Risk Alpha | (0.04) | |||
| Sortino Ratio | 0.0897 | |||
| Treynor Ratio | 0.2237 | |||
| Maximum Drawdown | 31.78 | |||
| Value At Risk | (6.30) | |||
| Potential Upside | 8.12 | |||
| Downside Variance | 13.63 | |||
| Semi Variance | 11.82 | |||
| Expected Short fall | (4.30) | |||
| Skewness | 1.52 | |||
| Kurtosis | 5.11 |
Beam Therapeutics Backtested Returns
Beam Therapeutics appears to be not too volatile, given 3 months investment horizon. Beam Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0923, which signifies that the company had a 0.0923 % return per unit of standard deviation over the last 3 months. We have found twenty-eight technical indicators for Beam Therapeutics, which you can use to evaluate the volatility of the firm. Please makes use of Beam Therapeutics' risk adjusted performance of 0.0747, and Mean Deviation of 3.43 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Beam Therapeutics holds a performance score of 7. The firm shows a Beta (market volatility) of 1.8, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Beam Therapeutics will likely underperform. Please check Beam Therapeutics' sortino ratio, semi variance, and the relationship between the information ratio and value at risk , to make a quick decision on whether Beam Therapeutics' price patterns will revert.
Auto-correlation | 0.09 |
Virtually no predictability
Beam Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between Beam Therapeutics time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Beam Therapeutics price movement. The serial correlation of 0.09 indicates that less than 9.0% of current Beam Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.09 | |
| Spearman Rank Test | -0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 6.99 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Beam Therapeutics Correlation, Beam Therapeutics Volatility and Beam Therapeutics Performance module to complement your research on Beam Therapeutics. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Beam Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.